MaxCyte, Inc. Director/PDMR Shareholding (1438N)

TIDMMXCT

RNS Number : 1438N

MaxCyte, Inc.

21 October 2016

MaxCyte, Inc.

("MaxCyte" or the "Company")

Driector/PDMR Sharedealing

Maryland, USA - 21 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based medicines, products and services, announces that it was notified on 20 October 2016 of the following transactions:

-- On 19 October 2016, John Johnston, a Non-Executive Director of the Company, purchased 37,500 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") at a price of 96 pence per share; and

-- On 20 October 2016, Mr Johnston, purchased 37,500 Ordinary Shares at a price of 98 pence per share, the ("Transactions").

Following the Transactions, Mr Johnston's total beneficial interest in the Company is 75,000 Ordinary Shares, representing approximately 0.17 per cent. of the current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
----  --------------------------------------------------------------- 
 a)    Name                       John Johnston 
----  -------------------------  ------------------------------------ 
 2     Reason for the notification 
----  --------------------------------------------------------------- 
 a)    Position/status            Non-Executive Director 
----  -------------------------  ------------------------------------ 
 b)    Initial                    Initial Notification 
        notification 
        /Amendment 
----  -------------------------  ------------------------------------ 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, auctioneer 
        or auction monitor 
----  --------------------------------------------------------------- 
 a)    Name                       MaxCyte, Inc. 
----  -------------------------  ------------------------------------ 
 b)    Legal Entity               N/A 
        Identifier 
----  -------------------------  ------------------------------------ 
 4     Details of the transaction(s): section to 
        be repeated for (i) each type of instrument; 
        (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions 
        have been conducted 
----  --------------------------------------------------------------- 
 a)    Description                Ordinary shares of 0.1 pence each 
        of the 
        financial 
        instrument,                MXCT / US57777K1060 
        type of 
        instrument 
 
        Identification 
        code 
----  -------------------------  ------------------------------------ 
 b)    Nature                     Purchase of shares 
        of the 
        transaction 
----  -------------------------  ------------------------------------ 
 c)    Currency                   GBP 
----  -------------------------  ------------------------------------ 
 d)    Price(s)                       Price(s)          Volume(s) 
        and volume(s) 
----  -------------------------  -----------------  ----------------- 
                                        0.98              37500 
 ------------------------------  -----------------  ----------------- 
                                        0.96              37500 
                                 -----------------  ----------------- 
 
 e)    Aggregated 
        information 
   - Aggregated 
    volume 
   - Price                         75000 
   - Aggregated                     0.97 
    total 
                                    GBP72,750 
 ------------------------------  ------------------------------------ 
 f)    Date of                    19/10/16 
        the transaction 
                                   20/10/16 
 ------------------------------  ------------------------------------ 
 g)    Place of                   London Stock Exchange, AIM 
        the transaction 
----  -------------------------  ------------------------------------ 
 

- ENDS -

For further information please contact:

 
 MaxCyte                                [phone] 
 Doug Doerfler, Chief Executive 
  Officer 
  Ron Holtz, Chief Financial 
  Officer 
 
 Nominated Adviser and Broker 
  Panmure Gordon 
  Freddy Crossley (Corporate 
  Finance) 
  Fabien Holler 
  Duncan Monteith 
  Tom Salvesen (Corporate Broking)      [phone] 
 
 Financial PR Advisor                   [phone] 
  Consilium Strategic Communications     [e-mail] 
 Mary-Jane Elliott 
  Chris Welsh 
  Lindsey Neville 
 

About MaxCyte

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit http://www.maxcyte.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEAKEFALAKFEF

(END) Dow Jones Newswires

October 21, 2016 02:43 ET (06:43 GMT)